Acarix AB (publ) (ACARIX) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everybody. Thank you for joining the Carex Q2 2025 earnings update. Appreciate everybody joining. And as usual, we will give a little bit of an update on who we are and what we do for any new investors that are joining us for the first time. Carex has the CADScore technology, which is an early cardiac diagnostic tool that is implemented at point of care that can help in really rapid assessment of coronary artery disease. We have an incredible negative predictive value that's proven by clinical trials, and we are the only company in the world in this space that has gone head-to-head with the standard of care, which is CTA in our clinical trials. In those clinical trials, per FDA approval, we have a 96.2% negative predictive value, and in Europe, with the CE mark, we have a 97.2 predictive value. Well on course, and if not better, than more invasive and longer timeline testing for risk stratification in coronary artery disease. We've been in business for over 15 years, have R&D going for the entire period. We have 45 patents to date, and we have over 6,000 patients in clinical trials and over 47,000 uses worldwide. Fairly mature company for a relatively startup organization as we function today. As mentioned, we're a class two device. We have FDA approval as well as CE Mark. We're headquartered in Sweden, and most of our R&D and production is done in Denmark, in Copenhagen, and we have global sales initiatives all around the world. A little bit about where we're at. Continuous progress in Q2, as we all discussed last quarter, as well as this quarter, we've seen a tremendous amount of geopolitical tension, rhetoric, business challenges, new administration in the US, massive changes via Doge, and then implementation of reduction in force, and now we're incr...